CIBRN Poll: With the expanding number of options available for treating specific conditions, is there merit in limiting choice by using a stratified or step approach to selection?

If you haven’t yet participated in the poll, we invite you to share your views:

With the expanding number of options available for treating specific conditions, is there merit in limiting choice by using a stratified or step approach to selection?

  • Yes, stratification should be used with the more costly biologic therapies.
  • Yes, stratification should be used for all classical and biologic therapies.
  • No, physicians and patients should be free to select any biologic therapy after failing traditional classical therapies.
  • No, physicians and patients should be free to select any classical or biologic therapy in any order once systemic therapy is indicated.

Click here to answer

Now Available Online: Archived recording of CIBRN Webinar #2 of 2019, originally hosted live on June 19, 2019

We invite you to view the archived recording of CIBRN Webinar #2 of 2019, which was hosted live by the CIBRN Leaders on June 19, 2019. Click to view the video: http://bit.ly/2FZ7crQ

The webinar will review the the following discussions in the CIBRN community:

  • CIBRN 2019 Q3: Are you aware of Health Canada’s new policy on the naming of biologic reference drugs and their biosimilars? Do you think it is sufficient to prevent confusion between drugs and to allow for proper pharmacovigilance? [View 2 replies to date]
  • CIBRN 2019 Q4: Aside from any scientific concerns, do you feel prepared to handle conversations with patients around transitioning (non-medical switching) of stable patients on reference biologics to biosimilars? Do you have the resources available to manage this situation? If not, what resources would you require? [View 2 replies to date]

Click to view the video: http://bit.ly/2FZ7crQ

Now Available Online: Archived recording of CIBRN Webinar #1 of 2019, originally hosted live on May 22, 2019

We invite you to view the archived recording of CIBRN Webinar #1 of 2019 which was hosted live by the CIBRN Leaders on May 22, 2019. Click to view the video: http://bit.ly/2WJLldN

The webinar reviews the following discussions and podcast in the CIBRN community:

  • CIBRN 2019 Q1: Should drug approvals be based on efficacy and demonstrated need, or should pharmacoeconomics be a larger consideration? [View 5 replies to date]
  • CIBRN 2019 Q2: Should manufacturers’ rebates be kept confidential, or should full transparency be expected, in order to more properly compare costs between originators and biosimilars? [View 4 replies to date]
  • CIBRN Podcast Episode 1: Dr. Philip Baer on “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18) [Listen to the podcast]

Click to view the video: http://bit.ly/2WJLldN

Join the CIBRN Leaders for a webinar on Wednesday, Jun 19, 8:30 pm ET.

Please join the CIBRN Leaders for Webinar 2 of 2019 on Wednesday, Jun 19 at 8:30 pm ET. The webinar will review the recent discussions and podcast in the CIBRN community:

  • CIBRN 2019 Q3: Are you aware of Health Canada’s new policy on the naming of biologic reference drugs and their biosimilars? Do you think it is sufficient to prevent confusion between drugs and to allow for proper pharmacovigilance? [View 2 replies to date]
  • CIBRN 2019 Q4: Aside from any scientific concerns, do you feel prepared to handle conversations with patients around transitioning (non-medical switching) of stable patients on reference biologics to biosimilars? Do you have the resources available to manage this situation? If not, what resources would you require? [View 2 replies to date]

To connect to the webinar:

Step 1: Join the teleconference at 1-866-830-9434 and enter PIN 7994216

Step 2: Join the web portion by clicking on this link: https://studio7communications.adobeconnect.com/cibrn_june19_2019/

Updated Canadian Rheumatology Association (CRA) Position Statement on Biosimilars

From the Canadian Rheumatology Association (May 21, 2019):

As evidence for the benefits and risks of using biosimilars in the management of rheumatic diseases has grown rapidly, the Canadian Rheumatology Association (CRA) has updated its position statement on biosimilars accordingly. We have undertaken this initiative to ensure that you and your patients are in possession of up-to-date guidance regarding the use and potential benefits and risks of biosimilars so that informed and appropriate treatment decisions may be made.

Please click here to view the updated position statement and FAQ’s.

Note that the CIBRN Leaders will be discussing this updated position policy at the CIBRN webinar to be held Wednesday, May 21 2019. See webinar connection details here.

 

Join the CIBRN Leaders for a webinar on Wednesday, May 22, 9:00 pm ET.

Please join the CIBRN Leaders for Webinar 1 of 2019 on Wednesday, May 22 at 9:00 pm ET. The webinar will review the recent discussions and podcast in the CIBRN community:

  • CIBRN 2019 Q1: Should drug approvals be based on efficacy and demonstrated need, or should pharmacoeconomics be a larger consideration? [View 5 replies to date]
  • CIBRN 2019 Q2: Should manufacturers’ rebates be kept confidential, or should full transparency be expected, in order to more properly compare costs between originators and biosimilars? [View 4 replies to date]
  • CIBRN Podcast Episode 1: Dr. Philip Baer on “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18) [Listen to the podcast]

To connect to the webinar:

Step 1: Join the teleconference at 1-866-830-9434 and enter PIN 7994216

Step 2: Join the web portion by clicking on this link:
https://studio7communications.adobeconnect.com/cibrn_may22_2019/